MDT-AP-3086
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 76.44
- os_event
- true
- age_years
- 18
- sex
- M
- new_clusters
- S1
- umap1_2d
- -0.242886001
- umap2_2d
- -11.86698207
- umap1_3d
- -2.149493639
- umap2_3d
- -0.023193485
- umap3_3d
- 5.371004897
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.280
- BILE_ACID_METABOLISM+0.140
- KRAS_SIGNALING_DN+0.120
- KRAS_SIGNALING_UP+0.100
- ALLOGRAFT_REJECTION+0.090
- UV_RESPONSE_DN+0.070
- COAGULATION+0.040
- ANGIOGENESIS+0.020
- XENOBIOTIC_METABOLISM+0.010
- MYOGENESIS+0.000
Top 10 suppressed
- G2M_CHECKPOINT-0.470
- E2F_TARGETS-0.460
- INTERFERON_ALPHA_RESPONSE-0.360
- TGF_BETA_SIGNALING-0.360
- MTORC1_SIGNALING-0.340
- MITOTIC_SPINDLE-0.280
- DNA_REPAIR-0.270
- IL6_JAK_STAT3_SIGNALING-0.270
- INTERFERON_GAMMA_RESPONSE-0.270
- PI3K_AKT_MTOR_SIGNALING-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3068 | Med | Medulloblastoma | 0.900 |
| 2 | MDT-AP-1101 | Med | Medulloblastoma | 0.880 |
| 3 | SRR13311172 | — | — | 0.869 |
| 4 | SRR8943002 | — | — | 0.853 |
| 5 | MDT-AP-0706 | Med | Medulloblastoma | 0.852 |
| 6 | SRR8942979 | — | — | 0.846 |
| 7 | TCGA-CF-A3MF-01A-12R-A21D-07 | — | — | 0.844 |
| 8 | SRR1394566 | GTEX | — | 0.843 |
| 9 | SRR1444678 | GTEX | — | 0.841 |
| 10 | TCGA-DK-A3IK-01A-32R-A21D-07 | — | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.120 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.090 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.070 | Inavolisib | — uncovered |
| COAGULATION | 0.040 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |